Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022

Abstract

What is already known about this topic? Real-world data on the magnitude and durability of protection by JYNNEOS vaccine against monkeypox (mpox) remain limited. What is added by this report? Among JYNNEOS vaccine-eligible men aged 18–49 years in 43 U.S. jurisdictions, mpox incidence among unvaccinated persons was 9.6 times as high as that among persons who had received 2 vaccine doses and 7.4 times as high as that among persons who had received only the first dose. Preliminary evidence indicates no difference in protection between subcutaneous and intradermal administration routes. What are the implications for public health practice? Although further study is needed to determine the magnitude and durability of protection, evidence indicates that JYNNEOS vaccination provides protection against mpox. Vaccine-eligible persons should complete the 2-dose vaccination series.